256 related articles for article (PubMed ID: 27978799)
1. Topoisomerases and Anthracyclines: Recent Advances and Perspectives in Anticancer Therapy and Prevention of Cardiotoxicity.
Mordente A; Meucci E; Martorana GE; Tavian D; Silvestrini A
Curr Med Chem; 2017; 24(15):1607-1626. PubMed ID: 27978799
[TBL] [Abstract][Full Text] [Related]
2. Topoisomerase 2β: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity.
Vejpongsa P; Yeh ET
Clin Pharmacol Ther; 2014 Jan; 95(1):45-52. PubMed ID: 24091715
[TBL] [Abstract][Full Text] [Related]
3. Topoisomerases as anticancer targets.
Delgado JL; Hsieh CM; Chan NL; Hiasa H
Biochem J; 2018 Jan; 475(2):373-398. PubMed ID: 29363591
[TBL] [Abstract][Full Text] [Related]
4. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.
Pommier Y; Leo E; Zhang H; Marchand C
Chem Biol; 2010 May; 17(5):421-33. PubMed ID: 20534341
[TBL] [Abstract][Full Text] [Related]
5. Topoisomerase IIα, rather than IIβ, is a promising target in development of anti-cancer drugs.
Chen W; Qiu J; Shen YM
Drug Discov Ther; 2012 Oct; 6(5):230-7. PubMed ID: 23229142
[TBL] [Abstract][Full Text] [Related]
6. Exploring the effects of topoisomerase II inhibitor XK469 on anthracycline cardiotoxicity and DNA damage.
Keresteš V; Kubeš J; Applová L; Kollárová P; Lenčová-Popelová O; Melnikova I; Karabanovich G; Khazeem MM; Bavlovič-Piskáčková H; Štěrbová-Kovaříková P; Austin CA; Roh J; Štěrba M; Šimůnek T; Jirkovská A
Toxicol Sci; 2024 Mar; 198(2):288-302. PubMed ID: 38290791
[TBL] [Abstract][Full Text] [Related]
7. Discovery and Development of Topoisomerase Inhibitors as Anticancer Agents.
Kathiravan MK; Kale AN; Nilewar S
Mini Rev Med Chem; 2016; 16(15):1219-1229. PubMed ID: 27549098
[TBL] [Abstract][Full Text] [Related]
8. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.
Lyu YL; Kerrigan JE; Lin CP; Azarova AM; Tsai YC; Ban Y; Liu LF
Cancer Res; 2007 Sep; 67(18):8839-46. PubMed ID: 17875725
[TBL] [Abstract][Full Text] [Related]
9. DNA topoisomerase II structures and anthracycline activity: insights into ternary complex formation.
Dal Ben D; Palumbo M; Zagotto G; Capranico G; Moro S
Curr Pharm Des; 2007; 13(27):2766-80. PubMed ID: 17897022
[TBL] [Abstract][Full Text] [Related]
10. [Molecular determinants of response to topoisomerase II inhibitors].
Lansiaux A; Pourquier P
Bull Cancer; 2011 Nov; 98(11):1299-310. PubMed ID: 22023806
[TBL] [Abstract][Full Text] [Related]
11. Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells.
Pan X; Hartley JM; Hartley JA; White KN; Wang Z; Bligh SW
Phytomedicine; 2012 May; 19(7):618-24. PubMed ID: 22402246
[TBL] [Abstract][Full Text] [Related]
12. Interaction model for anthracycline activity against DNA topoisomerase II.
Moro S; Beretta GL; Dal Ben D; Nitiss J; Palumbo M; Capranico G
Biochemistry; 2004 Jun; 43(23):7503-13. PubMed ID: 15182192
[TBL] [Abstract][Full Text] [Related]
13. Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells.
Vavrova A; Jansova H; Mackova E; Machacek M; Haskova P; Tichotova L; Sterba M; Simunek T
PLoS One; 2013; 8(10):e76676. PubMed ID: 24116135
[TBL] [Abstract][Full Text] [Related]
14. The dual topoisomerase inhibitor A35 preferentially and specially targets topoisomerase 2α by enhancing pre-strand and post-strand cleavage and inhibiting DNA religation.
Zhao W; Jiang G; Bi C; Li Y; Liu J; Ye C; He H; Li L; Song D; Shao R
Oncotarget; 2015 Nov; 6(35):37871-94. PubMed ID: 26462155
[TBL] [Abstract][Full Text] [Related]
15. [Structural, mechanistic and functional insights into topoisomerase II].
Qin SY; Yuan YM; Hu X; Sun X; Su ZD
Sheng Li Xue Bao; 2016 Feb; 68(1):98-106. PubMed ID: 26915327
[TBL] [Abstract][Full Text] [Related]
16. DNA topoisomerase II enzymes as molecular targets for cancer chemotherapy.
Chikamori K; Grozav AG; Kozuki T; Grabowski D; Ganapathi R; Ganapathi MK
Curr Cancer Drug Targets; 2010 Nov; 10(7):758-71. PubMed ID: 20578986
[TBL] [Abstract][Full Text] [Related]
17. DNA-Damaging Anticancer Drugs - A Perspective for DNA Repair- Oriented Therapy.
Blasiak J
Curr Med Chem; 2017; 24(15):1488-1503. PubMed ID: 28120709
[TBL] [Abstract][Full Text] [Related]
18. Iron chelators with topoisomerase-inhibitory activity and their anticancer applications.
Rao VA
Antioxid Redox Signal; 2013 Mar; 18(8):930-55. PubMed ID: 22900902
[TBL] [Abstract][Full Text] [Related]
19. Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer.
Cardoso F; Durbecq V; Larsimont D; Paesmans M; Leroy JY; Rouas G; Sotiriou C; Renard N; Richard V; Piccart MJ; Di Leo A
Int J Oncol; 2004 Jan; 24(1):201-9. PubMed ID: 14654958
[TBL] [Abstract][Full Text] [Related]
20. DNA topoisomerases as molecular targets for anticancer drugs.
Buzun K; Bielawska A; Bielawski K; Gornowicz A
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1781-1799. PubMed ID: 32975138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]